Company · Private
BlueRock Therapeutics
Engineered cell therapies derived from induced pluripotent stem cells, with a lead Parkinson's programme.
Listing
Private
Ticker
—
Headquarters
Cambridge, US
Founded
2016
Technology
iPSC-derived cell therapy
Category
Longevity thesis
Manufactured, off-the-shelf cells make regenerative medicine scalable.
Programmes
- bemdaneprocelPhase 3
Parkinson's disease
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.